Evidence map›Paper›PMID 39682121›Full record

ArticleCancers2024

Downregulated Regucalcin Expression Induces a Cancer-like Phenotype in Non-Neoplastic Prostate Cells and Augments the Aggressiveness of Prostate Cancer Cells: Interplay with the G Protein-Coupled Oestrogen Receptor?

Lara R S Fonseca, Ricardo J P Carreira, Mariana Feijó, José E B Cavaco, Henrique J Cardoso, Cátia V Vaz, Marília I Figueira, Sílvia Socorro

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lara R S FonsecaCICS-UBI-Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilhã, Portugal.ORCID 0000-0002-8789-4048
Ricardo J P CarreiraCICS-UBI-Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilhã, Portugal.ORCID 0000-0001-5030-7957
Mariana FeijóCICS-UBI-Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilhã, Portugal.ORCID 0000-0002-5330-5276
José E B CavacoCICS-UBI-Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilhã, Portugal.ORCID 0000-0002-3879-733X
Henrique J CardosoCICS-UBI-Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilhã, Portugal.
Cátia V VazCICS-UBI-Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilhã, Portugal.
Marília I FigueiraCICS-UBI-Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilhã, Portugal.
Sílvia SocorroCICS-UBI-Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilhã, Portugal.ORCID 0000-0001-8181-488X

Funding

FEDER PPBI-POCI-01-0145-FEDER-022122Foundation for Science and Technology 2021.07367.BDFoundation for Science and Technology 2021.07634.BDFoundation for Science and Technology UID/Multi/00709/2020
6 · The paper itself

Abstract

BACKGROUND/

objectivesRegucalcin (RGN) is a calcium-binding protein and an oestrogen target gene, which has been shown to play essential roles beyond calcium homeostasis. Decreased RGN expression was identified in several cancers, including prostate cancer (PCa). However, it is unknown if the loss of RGN is a cause or a consequence of malignancy. Also, it needs confirmation if RGN oestrogenic regulation occurs through the G-protein-coupled oestrogen receptor (GPER). This study investigates how

methodsBioinformatic analysis assessed the relationship between RESULTS/

conclusionsBioinformatic analysis showed that the loss of

Indexed as

G-protein-coupled oestrogen receptormetabolismmetastisationprostate cancerregucalcinsurvival

Identifiers

PMID39682121
PMCPMC11640704

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.